The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
Study sponsor: COMPASS Pathways
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-10-14Actual
Enrollment · participants19Actual
Source updated2023-11-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.